Type 2 Diabetes

Diabetes in Control Publisher Steve Freed meets with Dr. Richard Bergman at the 75th ADA Scientific Sessions in Boston. In this first installment, Dr. Bergman shares his start in diabetes research and explains the high points of his presentation, Comparative Methods for Assessment of Insulin Sensitivity: Oral Vs. Intravenous. Dr. Richard Bergman is the founder and director of Diabetes and Obesity Research Institute, Biomedical Sciences at Cedars-Sinai in Los Angeles. He introduced the use of engineering principles to understand the pathogenesis of diabetes.

Man, 52 years of age, type 2 diabetes, obesity class II on Victoza. He was very pleased with treatment response, lowering glucose levels, feeling full and more satisfied, but having a skin reaction.

FACT: Up to two-thirds of eligible Hispanics are not taking statins.

Study focuses on older women who sleep 6 hours or less or increase sleep duration by 2 hours or more over several years.

Mediterranean, low-fat, high complex carbohydrate diets focus of study.

Male, 72 years of age, type 2 diabetes, overweight secondary to binge eating disorder. Taking glipizide 20mg daily and metformin 1,000mg twice daily. Hypoglycemic unawareness. Not regularly checking glucose. Recent A1C 6.8%.

Risks of death varied depending on age, glycemic control and renal complications.

HbA1c and lipids show improved with high-intensity physical activity.

New study suggests triple therapy improves glycemic control.

Recent study suggests that compelling biomarkers may predict major adverse outcomes, including death, in diabetes.